Indivior Patent-Cliff Exposure & CMS Drug Spending Portfolio
Indivior (North Chesterfield, VA): 4 reconciled FDA prescription therapies (58.0% 2025 to 2030 cliff risk), $1.66B 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | North Chesterfield, VA |
| Reconciled FDA Portfolio Therapies | 4 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 58.0% |
| Primary Portfolio LOE Date | 2030-01-01 |
| 2024 CMS Total Public Spend | $1.66B |
| 2024 Medicare Part D Spend | $169.5M |
| 2024 Medicaid Spend | $1.49B |
| California HCAI SB 17 Filings | 0 statutory filings in 2023 to 2026 panel |